Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01444430 · ClinicalTrials.gov registry record · Phase 3
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 12,460
- Enrollment target
NCT01444430 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 12,460 participants.
The verdict
NCT01444430, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12,460 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety of Symbicort compared to inhaled corticosteroid alone during 6 months in adult and adolescent patients with asthma
Interventions
- DRUG Symbicort pMDI
- DRUG budesonide pMDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,460 participants |
| Start Date | 2011-12 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01444430
The ClinicalTrials.gov registry entry for NCT01444430 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 12,460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Symbicort pMDI is the first listed.
NCT01444430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01444430 about?
NCT01444430 is a clinical study titled "A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents". The purpose of the study is to evaluate the safety of Symbicort compared to inhaled corticosteroid alone during 6 months in adult and adolescent patients with asthma
What is the current status of trial NCT01444430?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12,460 participants. The study started on 2011-12. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01444430?
The interventions under investigation include: Symbicort pMDI (DRUG), budesonide pMDI (DRUG).
Who is sponsoring clinical trial NCT01444430?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.